Valeant-Takeda Salix Negotiations Bust On $10 Billion Price: Report

Valeant Pharmaceuticals' (VRX) sales force expansion for two stomach drugs could signal failed negotiations to sell its Salix Pharmaceuticals unit, Mizuho analyst Irina Koffler said Wednesday amid a similar report from The Wall Street Journal.

Acquisition talks between Valeant and Japanese firm Takeda Pharmaceuticals broke down during an 11th-hour price disagreement, inside sources told the WSJ. Valeant officials didn't immediately return a request for comment from IBD.

Takeda would have...

What feeling does this article give you?

#hashtags to follow:

Valeant Pharmaceuticals [+]    VRX [+]    Salix Pharmaceuticals [+]    Mizuho [+]    Irina Koffler [+]    Wall Street Journal [+]    Valeant and Japanese [+]    Takeda Pharmaceuticals [+]    WSJ [+]    IBD [+]    Takeda [+]   

More #news: